Uncategorized
Glaukos Corporation Receives Regulatory Approval in Australia for iStent inject®
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) for its iStent inject® Trabecular Micro-Bypass Stent. With TGA approval, the iStent inject is now indicated for use in Australia in conjunction with cat
